Last reviewed 2026-04-23 · How we verify

Dehydroepiandrosterone, BAY86-5314

Dehydroepiandrosterone, BAY86-5314 is a Small molecule drug developed by Bayer. It is currently in Phase 2 development for Fatigue.

Dehydroepiandrosterone is a naturally occurring steroid hormone that has been investigated for its potential therapeutic effects.

Dehydroepiandrosterone (DHEA) is being evaluated by Bayer as an adjunct therapy to oral contraceptives for women with reduced libido. Phase 2 trials have been completed, showing potential efficacy and safety. The drug is not yet FDA-approved but has shown promise in addressing a significant unmet need.

At a glance

Mechanism of action

Dehydroepiandrosterone is a precursor to androgen and estrogen hormones, and its administration has been explored for various conditions, including fatigue, depression, and osteoporosis. However, its exact mechanism of action is not fully understood.

Approved indications

• Fatigue

Common side effects

• Hirsutism
• Acne
• Hypertension

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Dehydroepiandrosterone, BAY86-5314 CI brief — competitive landscape report
• Dehydroepiandrosterone, BAY86-5314 updates RSS · CI watch RSS
• Bayer portfolio CI

Frequently asked questions about Dehydroepiandrosterone, BAY86-5314

Related

• Manufacturer: Bayer — full pipeline
• Therapeutic area: All drugs in Oncology, Endocrinology
• Indication: Drugs for Fatigue
• Compare: Dehydroepiandrosterone, BAY86-5314 vs similar drugs
• Pricing: Dehydroepiandrosterone, BAY86-5314 cost, discount & access